Abstract:Abstract Background Fluconazole, an antifungal drug, prevents fungi growth by inhibiting the formation of a protective covering. Ivermectin has several biological activities, such as antibacterial, antiviral, and anti-cancer characteristics, and offers various therapeutic outcomes. There are several commercial products containing these two drugs. Therefore, developing a method that can allow the simultaneous estimation of Fluconazole and ivermectin is inevitable to monitor them in commercial dosage forms. The hyphenated methodology that combines spectroscopic and chromatographic techniques is gaining high interest in the pharmaceutical industry. Consequently, the objective of present research work was to investigate robust and sensitive LC–MS/MS avenue for simultaneous determination of Fluconazole and ivermectin in pure material and combined dosage form. Results The simultaneous quantification of Fluconazole and ivermectin in tablet dosage form has been developed and validated using a straightforward, sensitive, practical, and repeatable LC–MS/MS approach. The separation was performed using a C 18 (150 × 4.6 mm) column, injection volume of 10 μL, and elution with acetonitrile: formic acid at a ratio of 70:30, with the column temperature at 30 °C, and a flow rate of 4.0 mL/min. The retention times of Ivermectin and Fluconazole were 1.10 min and 1.05 min, respectively. The calibration curves for Fluconazole and ivermectin demonstrated significant linearities indicated by the correlation coefficients (r 2 = 0.999 and r 2 = 0.997) and precision (% R.S.D. of 1.58 and 1.13). The linear correlation between peak area and concentration allowed high percentage recoveries of 98.5%–99.4% and 97.8%–99.3% for Fluconazole and Ivermectin, respectively. The L.O.D.s for Fluconazole and ivermectin were found to be 0.0034 and 0.074 g/mL, respectively. The L.O.Q.s for Fluconazole and ivermectin were 0.010 and 0.225 g/mL, respectively. Conclusion All the analytical parameters were identified and found to be within the acceptable range set forth by the ICH guidelines, demonstrating the devised method's acceptability in the simultaneous detection and estimation of Fluconazole and ivermectin in the commercial dosage forms.

HPLC-MS Determination Concentration of Fluconazole and the Impact of Plagiochin E in Candida Albicans

Development and Validation of a Sensitive LC-MS/MS Method for Determination of Intracellular Concentration of Fluconazole in Candida Albicans.

Liquid chromatography-tandem mass spectrometric method for the analysis of fluconazole and evaluation of the impact of phenolic compounds on the concentration of fluconazole in Candida albicans.

The Effect of Plagiochin E Alone and in Combination with Fluconazole on the Ergosterol Biosynthesis of Candida Albicans.

Primary Study on Antifungal Activities and Reversal of Fluconazole Resistance of Plagiochin E

New analytical LC–MS/MS method for fluconazole and ivermectin estimation in combined pharmaceutical dosage form: development and validation

Plagiochin E, a Botanic-Derived Phenolic Compound, Reverses Fungal Resistance to Fluconazole Relating to the Efflux Pump.

The Effect of Dihydromyricetin on the Pharmacokinetics of Fluconazole in Sprague-Dawley Rat Plasma, Based on High-Performance Liquid Chromatography-Tandem Mass Spectrometry

Synergistic Antifungal Effect of Fluconazole Combined with Licofelone Against Resistant Candida Albicans

Determination of Fluconazole and its Relative Bioavailability in Human Plasma by HPLC-MS

DNA Microarray Analysis of Fluconazole Resistance in a Laboratory Candida Albicans Strain.

Determination of Fluconazole Concentration in Human Serum by RP-HPLC and Its Clinical Application

Retracted: the Effect of Plagiochin E Alone and in Combination with Fluconazole on the Ergosterol Biosynthesis of Candida Albicans (retracted Article. See Vol 32, Pg 1135, 2009)

RP-HPLC determination of fluconazole concentrations in human plasma and its application

Embryo Tissue and Plasma Concentration of Fluconazole in Pregnant Women Assayed by HPLC

Synergistic Effect Of Pseudolaric Acid B With Fluconazole Against Resistant Isolates And Biofilm Of Candida Tropicalis

A mechanism study on the synergistic effects of rifapentine and fluconazole against fluconazole-resistant Candida albicans in vitro

In vitro synergy of pseudolaric acid B and fluconazole against clinical isolates of Candida albicans: Synergy of PAB and FLC against Candida albicans

Proteomic analysis of plasma membrane from fluconazole-resistant Candida albicans

Antifungal Activity of the Ethanol Extract from Flos Rosae Chinensis with Activity Against Fluconazole-Resistant Clinical Candida

Antifungal evaluation of quinoline-chalcone derivatives combined with FLC against drug-resistant Candida albicans.